Roche Introduces cobas MPX-E Assay, a 4-in-1 Donor Screening Test to Enhance Global Blood Safety
Roche Launches cobas MPX-E, a 4-in-1 Donor Screening Assay to Strengthen Global Blood Supply Safety Roche has announced the availability of its cobas® MPX-E assay, a next-generation qualitative in vitro…
Incyte Highlights Positive 54-Week Povorcitinib Data at AAD 2026
Incyte Reports Positive 54-Week Late-Breaking Povorcitinib Data in Hidradenitis Suppurativa at AAD 2026 Incyte has reported new long-term findings from its pivotal Phase 3 STOP-HS clinical development program, highlighting the…
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents with Symptomatic oHCM
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescents with Symptomatic oHCM Bristol Myers Squibb has announced compelling results from its pivotal Phase 3 SCOUT-HCM clinical…
Phase 2 CADENCE Trial Confirms Proof-of-Concept for WINREVAIR™ in CpcPH-HFpEF Patients
Phase 2 CADENCE Trial Shows Positive Results, Establishing WINREVAIR™ as a Proof-of-Concept Therapy in CpcPH and HFpEF Merck & Co.—known as MSD outside the United States and Canada—has unveiled comprehensive…
Bepirovirsen Gains European Medicines Agency Review as a Potential First-in-Class Therapy for Chronic Hepatitis B
Bepirovirsen advances to regulatory review by the European Medicines Agency as a promising first-in-class therapy for chronic hepatitis B GSK plc has announced a significant regulatory milestone as the European…
Novartis to Acquire Excellergy, Inc., Strengthening Allergy Leadership with Next-Generation Anti-IgE Innovation
Novartis Agrees to Acquire Excellergy, Inc. to Strengthen Allergy Leadership with Next-Generation Anti-IgE Innovation Novartis has announced a strategic agreement to acquire Excellergy, a privately held biotechnology company focused on…
AbbVie to Present New Data Advancing Care in Immune-Mediated Skin Diseases at AAD 2026
AbbVie to Present New Clinical and Real-World Evidence Advancing Care Standards in Immune-Mediated Skin Diseases at the AAD Annual Meeting 2026 AbbVie has announced a comprehensive slate of new research…
Eli Lilly and Company’s EBGLYSS Shows Up to Four Years of Sustained Control in Atopic Dermatitis
Eli Lilly and Company Reports Up to Four Years of Sustained Disease Control with EBGLYSS (lebrikizumab-lbkz) in Moderate-to-Severe Atopic Dermatitis Eli Lilly and Company has unveiled compelling new long-term data…
Real Time Medical Systems to Showcase How Live Data Enhances Clinical Standards and Survey Readiness at PALTC26
Real Time Medical Systems to Showcase How Live Data Enhances Clinical Standards and Survey Readiness at PALTC26 Real Time Medical Systems, widely recognized as a leading provider of post-acute care…
Sensus Healthcare Files Breach of Contract Lawsuit Against SkinCure Oncology
Sensus Healthcare Files Breach of Contract Lawsuit Against SkinCure Oncology Sensus Healthcare, Inc., a developer of non-invasive and minimally invasive technologies for the treatment of both oncological and non-oncological skin…
LEO Pharma Highlights Long-Term SPEVIGO® Data in GPP at AAD 2026
LEO Pharma Presents New Long-Term Data for SPEVIGO® (spesolimab-sbzo) in Adults with Generalized Pustular Psoriasis at AAD 2026 LEO Pharma A/S has announced new long-term clinical data supporting the use…
Banner|Aetna Joins Community in Supporting the 2026 Phoenix Heart Walk
Banner|Aetna Engages Community at the 2026 Phoenix Heart Walk Banner|Aetna, an integrated health plan formed through a collaboration between Banner Health and CVS Health through its Aetna business, is actively…